VANCOUVER, BC, Nov. 7, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended September 30, 2025.

"This quarter, we achieved several significant regulatory and clinical milestones, including the first-ever approval for compassionate use of psilocybin in the European Union, and new phase 2 authorizations in both the United States and the United Kingdom," said Benjamin Lightburn, Chief Executive Officer and Co-Founder at Filament Health. "These developments continue to validate our botanical drug development platform and underscore growing global recognition of Filament's leadership in the industry."

Q3 2025 Operational & Financial Highlights:

• On July 31, 2025, the Company announced the first-ever approval for compassionate use of psilocybin in the European Union towards administration to a patient suffering from treatment-resistant depression in Germany.
• On July 24, 2025, the Company announced a partnership with University College London to supply its botanical psilocybin drug candidate, PEX010, for two phase 2 clinical trials to explore effects on brain function, perception, and psychological wellbeing.
• On July 7, 2025, the Company announced that the U.S. Food and Drug Administration has authorized a phase 2 clinical trial at the University of Washington studying its botanical psilocybin drug candidate, PEX010, for the treatment of alcohol use disorder and post-traumatic stress disorder in military veterans and first responders.
• Cash and cash equivalents of $337,082;
• Cash used in operating activities of $893,566;
• Deferred revenues of $181,732; and total revenues of $268,522.

ABOUT FILAMENT HEALTH (OTC:FLHLF)

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.

Learn more at www.filament.healthand on X, Instagram, and LinkedIn.

FORWARD LOOKING INFORMATION

Certain statements and information contained herein may constitute "forward-looking statements" and "forward-looking information," respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning the impact of the patent on the Company's business and the ability of the Company to secure future patents. Forward-looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including status of patent applications and the ability to secure patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.